Date: 2014-11-11
Type of information: Development agreement
Compound: companion diagnostics
Company: Novartis (Switzerland) Qiagen (The Netherlands)
Therapeutic area:
Type agreement: development
Action mechanism:
Disease:
Details: * On November 11, 2014, Qiagen announced it has entered into a master collaboration agreement with Novartis AG to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its development pipeline. The non-exclusive agreement with Novartis creates a framework for collaborations that would include developing Qiagen companion diagnostics to guide treatment decisions for Novartis pharmaceutical products. The scope of the collaboration can cover all Qiagen platforms, indications or biomarkers. The collaboration with Novartis is the ninth master framework agreement reached by Qiagen for the development of companion diagnostics, underscoring its position as the preferred partner to pharma companies.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
